Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, Jilin, China.
Department of Endocrinology, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Bioengineered. 2021 Dec;12(2):10994-11006. doi: 10.1080/21655979.2021.2004979.
MicroRNAs play important roles in atherosclerogenesis and are important novel pharmaceutic targets in atherosclerosis management. The whole spectrum of miRNAs dysregulation is still under intense investigation. This study intends to identify more novel dysregulated microRNAs in atherosclerotic mice. Half of eight-week-old male ApoE-/- mice were fed with high-fat-diet for 12 weeks as a model mice, and the remaining half of ApoE-/- mice were fed with a normal-diet as a control. A serum lipid profile was performed with ELISA kits, and atherosclerotic lesions were assessed. Aortic tissues were dissected for gene expression profiling using a Multispecies miRNA 4.0 Array, and significant differentially expressed miRNAs were identified with fold change ≥ 2 and p < 0.05. Real-time quantitative PCR was used to validate microarray gene expression data on selected genes. Predicted target genes were extracted and subjected to bioinformatic analysis for molecular function and pathway enrichment analysis. Model mice showed a 15.32% atherosclerotic lesion compared to 1.52% in the control group. A total of 25 significant differentially expressed microRNAs were identified, with most of them (24/25) downregulated. Real-time quantitative PCR confirmed the GeneChip data. Bioinformatic analysis of predicted target genes identified high involvement of the PI3K/Akt/mTOR signaling pathway. Microarray profiling of miRNAs in high-fat-fed Model mice identified 25 differentially expressed miRNAs, including some novel miRNAs, and the PI3K/Akt/mTOR signaling pathway is highly enriched in the predicted target genes. The novel identified dysregulated miRNAs suggest a broader spectrum of miRNA dysregulation in the progression of atherosclerosis and provide more research and therapeutic targets for atherosclerosis.
微小 RNA 在动脉粥样硬化发生中发挥重要作用,是动脉粥样硬化治疗中重要的新型药物靶点。微小 RNA 失调的全貌仍在深入研究中。本研究旨在鉴定动脉粥样硬化小鼠中更多新的失调微小 RNA。将一半 8 周龄雄性 ApoE-/- 小鼠用高脂肪饮食喂养 12 周作为模型小鼠,另一半 ApoE-/- 小鼠用正常饮食作为对照。用 ELISA 试剂盒检测血清脂质谱,并评估动脉粥样硬化病变。用 Multispecies miRNA 4.0 Array 对主动脉组织进行基因表达谱分析,用 fold change≥2 和 p<0.05 鉴定显著差异表达的微小 RNA。用实时定量 PCR 验证所选基因的微阵列基因表达数据。提取预测靶基因并进行生物信息学分析,进行分子功能和途径富集分析。模型小鼠的动脉粥样硬化病变比对照组增加了 15.32%,而对照组为 1.52%。共鉴定出 25 个显著差异表达的微小 RNA,其中大多数(24/25)下调。实时定量 PCR 验证了 GeneChip 数据。预测靶基因的生物信息学分析表明,PI3K/Akt/mTOR 信号通路高度参与。高脂肪喂养模型小鼠的微小 RNA 微阵列分析鉴定出 25 个差异表达的微小 RNA,包括一些新的微小 RNA,预测靶基因中高度富集了 PI3K/Akt/mTOR 信号通路。新鉴定的失调微小 RNA 表明在动脉粥样硬化进展中存在更广泛的微小 RNA 失调谱,并为动脉粥样硬化提供了更多的研究和治疗靶点。